MX2022000050A - Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). - Google Patents

Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).

Info

Publication number
MX2022000050A
MX2022000050A MX2022000050A MX2022000050A MX2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A MX 2022000050 A MX2022000050 A MX 2022000050A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
bet inhibitors
inhibitors
bet
novel
Prior art date
Application number
MX2022000050A
Other languages
English (en)
Inventor
Sarvajit Chakravarty
Son Minh Pham
Jiyun Chen
Jayakanth Kankanala
Anup Barde
Anjan Kumar Nayak
Jeremy D Pettigrew
Chris P Miller
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of MX2022000050A publication Critical patent/MX2022000050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Se proporcionan nuevos inhibidores de bromodominio y dominio extraterminal (BET) y métodos terapéuticos para tratar afecciones y enfermedades utilizando estos nuevos inhibidores de BET.
MX2022000050A 2019-07-02 2020-07-01 Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet). MX2022000050A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870020P 2019-07-02 2019-07-02
US202063017547P 2020-04-29 2020-04-29
PCT/US2020/040566 WO2021003310A1 (en) 2019-07-02 2020-07-01 Heterocyclic compounds as bet inhibitors

Publications (1)

Publication Number Publication Date
MX2022000050A true MX2022000050A (es) 2022-05-24

Family

ID=74065335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000050A MX2022000050A (es) 2019-07-02 2020-07-01 Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).

Country Status (12)

Country Link
US (2) US11584756B2 (es)
EP (1) EP3997070A4 (es)
JP (1) JP7465945B2 (es)
KR (1) KR20220028072A (es)
CN (1) CN114286818A (es)
AU (1) AU2020299592A1 (es)
BR (1) BR112021026668A2 (es)
CA (1) CA3145827A1 (es)
CL (1) CL2021003513A1 (es)
IL (1) IL289439A (es)
MX (1) MX2022000050A (es)
WO (1) WO2021003310A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210038921A (ko) * 2018-07-25 2021-04-08 치아타이 티안큉 파마수티컬 그룹 주식회사 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도
CA3116931A1 (en) 2018-10-30 2020-05-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
WO2021222466A1 (en) * 2020-04-29 2021-11-04 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
GB2621505A (en) 2021-06-29 2024-02-14 Tay Therapeutics Ltd Pyrrolopyridone derivatives useful in the treatment of cancer
CN116135858A (zh) * 2021-11-16 2023-05-19 中国科学院广州生物医药与健康研究院 一种呋喃并吡啶酮类化合物及其应用
WO2023133284A2 (en) * 2022-01-06 2023-07-13 Design Therapeutics, Inc. Compounds and methods for treating friedreich's ataxia
CN114907335A (zh) * 2022-02-25 2022-08-16 陕西维世诺新材料有限公司 2-（苯并噻吩-2-基）苯并[d]惡唑衍生物、制备方法及应用
CN115028646B (zh) * 2022-05-31 2023-06-30 山东第一医科大学(山东省医学科学院) 一种含氮杂环类化合物、制备方法及在抗肿瘤制剂中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US8263772B2 (en) * 2006-06-08 2012-09-11 Eli Lilly And Company MCH receptor antagonists
WO2009054952A2 (en) 2007-10-22 2009-04-30 Angion Biomedica Corp. Small molecule inhibitors of parp activity
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
ES2625945T3 (es) 2012-11-14 2017-07-21 Glaxosmithkline Llc Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
BR112015022861A8 (pt) * 2013-03-11 2019-11-26 Abbvie Inc inibidores de bromodomínio
WO2014164596A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
EP2970330B1 (en) 2013-03-12 2019-04-17 AbbVie Inc. Tetracyclic bromodomain inhibitors
SG11201506245QA (en) 2013-03-14 2015-09-29 Glaxosmithkline Ip No 2 Ltd 2,3-disubstituted 1 -acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
MX2015017963A (es) 2013-06-28 2016-11-10 Abbvie Inc Inhibidores de bromodominio.
ES2930305T3 (es) * 2013-10-18 2022-12-09 Celgene Quanticel Res Inc Inhibidores del bromodominio
US9388161B2 (en) 2013-11-18 2016-07-12 Forma Therapeutics, Inc. Tetrahydroquinoline compositions as BET bromodomain inhibitors
US9422281B2 (en) 2013-11-18 2016-08-23 Forma Therapeutics, Inc. Benzopiperazine compositions as BET bromodomain inhibitors
JP6422164B2 (ja) 2013-12-26 2018-11-14 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
CA2934788C (en) 2014-01-09 2021-12-07 Orion Corporation Bicyclic heterocyclic derivatives as bromodomain inhibitors
JP2017511801A (ja) 2014-02-28 2017-04-27 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン ＢＥＴブロモドメイン阻害剤としての９Ｈ−ピリミド［４，５−ｂ］インドールおよび関連類似体
MX2016013851A (es) 2014-04-23 2017-07-14 Incyte Corp 1h-pirrolo[2,3-c]piridin-7(6h)-onas y pirazolo[3,4-c]piridin-7(6h) -onas como inhibidores de proteinas de bromodominio y extra terminal (bet).
AU2015314184B2 (en) 2014-09-12 2018-09-13 Glaxosmithkline Intellectual Property (No.2) Limited Tetrahydroquinoline derivatives as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CA2988209A1 (en) 2015-06-16 2016-12-22 Orion Corporation Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
CN108137585B (zh) 2015-09-21 2021-10-22 普莱希科公司 杂环化合物及其应用
JP6795588B2 (ja) 2015-09-22 2020-12-02 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
US10414735B2 (en) 2015-11-09 2019-09-17 Forge Therapeutics, Inc. Substituted hydroxypyrimidinones for treating bacterial infections
WO2017103670A1 (en) 2015-12-14 2017-06-22 Zenith Epigenetics Lid. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
JP6978424B2 (ja) 2016-04-15 2021-12-08 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3474900A4 (en) 2016-06-23 2020-03-11 Dana-Farber Cancer Institute, Inc. DEGRADATION OF PROTEIN 9 (BRD9) CONTAINING BROMANOMAIN BY CONJUGATING BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
WO2018130174A1 (zh) 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CA3086054A1 (en) 2017-12-20 2019-06-27 Betta Pharmaceuticals Co., Ltd Compound functioning as bromodomain protein inhibitor, and composition
EP3741758A4 (en) 2018-01-16 2020-11-25 Shanghai Institute of Materia Medica, Chinese Academy of Sciences BROMODOMAIN INHIBITOR COMPOUND AND ITS USE
CN110041253B (zh) 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
KR20210038921A (ko) 2018-07-25 2021-04-08 치아타이 티안큉 파마수티컬 그룹 주식회사 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도
WO2020063976A1 (zh) 2018-09-29 2020-04-02 如东凌达生物医药科技有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
CA3116931A1 (en) 2018-10-30 2020-05-07 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
WO2020160193A2 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
EP3967690A4 (en) 2019-03-17 2023-04-12 Shanghai Ringene BioPharma Co., Ltd. PYRROLE AMIDOPYRIDONE COMPOUND, METHOD FOR PREPARING IT AND ITS USE
CN112094266B (zh) 2019-06-17 2023-03-21 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
WO2021222466A1 (en) 2020-04-29 2021-11-04 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors

Also Published As

Publication number Publication date
KR20220028072A (ko) 2022-03-08
IL289439A (en) 2022-02-01
BR112021026668A2 (pt) 2022-02-15
US11584756B2 (en) 2023-02-21
EP3997070A1 (en) 2022-05-18
CN114286818A (zh) 2022-04-05
AU2020299592A1 (en) 2022-02-17
CA3145827A1 (en) 2021-01-07
WO2021003310A1 (en) 2021-01-07
US20230339964A1 (en) 2023-10-26
EP3997070A4 (en) 2023-07-26
CL2021003513A1 (es) 2022-10-28
US20210002293A1 (en) 2021-01-07
JP2022538917A (ja) 2022-09-06
JP7465945B2 (ja) 2024-04-11

Similar Documents

Publication Publication Date Title
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
PH12020550857A1 (en) Polycyclic compounds as allosteric shp2 inhibitors
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12020552214A1 (en) Ectonucleotidase inhibitors and methods of use thereof
CR20200362A (es) CICLOPROPILAMINA COMO INHIBIDORES DE LA LSD1 (Divisional 2016-0395)
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
EA201591382A1 (ru) Ингибиторы гистондеметилаз
MX2016010504A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas.
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
EA201590941A1 (ru) Гетероциклические ингибиторы глютаминазы
AU2018347307A1 (en) Heterocyclic compounds and uses thereof
CR20220325A (es) Fluoroalquil-oxadiazoles y sus usos
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2017015740A (es) Moduladores de ror gamma (ror?).
EA201790907A1 (ru) Новые производные пиразолопиримидина в качестве ингибиторов nik
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2022000845A (es) Compuestos inhibidores.
MX2021012418A (es) Compuestos heterociclicos y sus usos.
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена